Net cash provided by
operating activities 120,372 77,787
Investing Activities:
Capital expenditures (61,332) (67,059)
Acquisitions (4,931) (12,021)
Proceeds from dispositions of property
and intangible assets 941 19,848
Net cash used in investing activities (65,322) (59,232)
Financing Activities:
Proceeds from revolving line
of credit borrowings, net 25,000 8,000
Repayments of private placement notes (2,728) (2,727)
Repurchase of common stock (39,260) (29,994)
Proceeds from exercise of stock options 3,580 13,356
Dividend payments (10,127) (10,614)
Medicare Part D subsidy receipts
(disbursements), net (30,372) (5,937)
Excess tax benefits related to stock
awards and options 1,030 6,570
Other (2,325) (342)
Net cash used in financing activities (55,202) (21,688)
Decrease in cash and cash equivalents (152) (3,133)
Cash and cash equivalents at
beginning of period 27,019 27,596
Cash and cash equivalents at end of period 26,867 24,463
Supplemental disclosure of cash flow information:
Cash paid for interest, net of
amounts capitalized $5,348 $3,476
Cash paid for income taxes 44,663 16,402
Condensed Statements of Consolidated Stockholders' Equity<
'/>"/>
| SOURCE Longs Drug Stores Corporation Copyright©2008 PR Newswire. All rights reserved |